» Articles » PMID: 29467650

Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition

Overview
Journal Front Pharmacol
Date 2018 Feb 23
PMID 29467650
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

High-throughput techniques allow for massive screening of drug combinations. To find combinations that exhibit an interaction effect, one filters for promising compound combinations by comparing to a response without interaction. A common principle for no interaction is Loewe Additivity which is based on the assumption that no compound interacts with itself and that two doses from different compounds having the same effect are equivalent. It then should not matter whether a component is replaced by the other or vice versa. We call this assumption the Loewe Additivity Consistency Condition (LACC). We derive explicit and implicit null reference models from the Loewe Additivity principle that are equivalent when the LACC holds. Of these two formulations, the implicit formulation is the known General Isobole Equation (Loewe, 1928), whereas the explicit one is the novel contribution. The LACC is violated in a significant number of cases. In this scenario the models make different predictions. We analyze two data sets of drug screening that are non-interactive (Cokol et al., 2011; Yadav et al., 2015) and show that the LACC is mostly violated and Loewe Additivity not defined. Further, we compare the measurements of the non-interactive cases of both data sets to the theoretical null reference models in terms of bias and mean squared error. We demonstrate that the explicit formulation of the null reference model leads to smaller mean squared errors than the implicit one and is much faster to compute.

Citing Articles

The many dimensions of combination therapy: How to combine antibiotics to limit resistance evolution.

Nyhoegen C, Bonhoeffer S, Uecker H Evol Appl. 2024; 17(8):e13764.

PMID: 39100751 PMC: 11297101. DOI: 10.1111/eva.13764.


Synergy between the clavanins as a weapon against multidrug-resistant .

Naing M, Juliano S, Angeles-Boza A RSC Med Chem. 2024; 15(6):2160-2164.

PMID: 38911167 PMC: 11187565. DOI: 10.1039/d4md00070f.


Pharmacokinetics-Pharmacodynamics Modeling for Evaluating Drug-Drug Interactions in Polypharmacy: Development and Challenges.

Zhao D, Huang P, Yu L, He Y Clin Pharmacokinet. 2024; 63(7):919-944.

PMID: 38888813 DOI: 10.1007/s40262-024-01391-2.


Guiding model-driven combination dose selection using multi-objective synergy optimization.

Gevertz J, Kareva I CPT Pharmacometrics Syst Pharmacol. 2023; 12(11):1698-1713.

PMID: 37415306 PMC: 10681518. DOI: 10.1002/psp4.12997.


Synergism: biocontrol agents and biostimulants in reducing abiotic and biotic stresses in crop.

Anuar M, Hashim A, Ho C, Wong M, Sundram S, Saidi N World J Microbiol Biotechnol. 2023; 39(5):123.

PMID: 36934342 DOI: 10.1007/s11274-023-03579-3.


References
1.
Chou T, Talalay P . A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem. 1977; 252(18):6438-42. View

2.
Ritz C, Baty F, Streibig J, Gerhard D . Dose-Response Analysis Using R. PLoS One. 2015; 10(12):e0146021. PMC: 4696819. DOI: 10.1371/journal.pone.0146021. View

3.
Lehar J, Zimmermann G, Krueger A, Molnar R, Ledell J, Heilbut A . Chemical combination effects predict connectivity in biological systems. Mol Syst Biol. 2007; 3:80. PMC: 1828746. DOI: 10.1038/msb4100116. View

4.
BERENBAUM M . The expected effect of a combination of agents: the general solution. J Theor Biol. 1985; 114(3):413-31. DOI: 10.1016/s0022-5193(85)80176-4. View

5.
Cokol M, Chua H, Tasan M, Mutlu B, Weinstein Z, Suzuki Y . Systematic exploration of synergistic drug pairs. Mol Syst Biol. 2011; 7:544. PMC: 3261710. DOI: 10.1038/msb.2011.71. View